drugset / Trial / NCT04139226

A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With Omeprazole

NCT04139226

Phase 1 Completed 44 enrolled Amgen
NaSingle-groupOpen-labelTreatment

Summary

This is a two-part study to be conducted at single study center, (additional center(s) may be selected if needed) to assess the safety, tolerability, PK and PD parameters for a new SDD formulation of CC-11050 in healthy subjects. The effects of a high-fat meal and omeprazole will also be assessed. Blood samples will be collected at prespecified times for PK, clinical laboratory safety assessments, PD (Part 1 only), and/or exploratory analyses. Safety will be monitored throughout the study from the time the ICF is signed through study completion.

Timeline

Start
2019-08-28
Primary completion
2020-02-27
Completion
2020-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Dovramilast Small molecule

Indications

No indication recorded.